drugset / Trial / NCT07462923
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NaSequentialOpen-labelTreatment
Summary
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 1b, open-label, multi-center study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HS-20093 in patients with advanced gastric and gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2026-01-29
- Primary completion
- 2026-12-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-20093 | Other / unclassified | 6 mg/kg | Intravenous |
| Subject | HS-20093 | Other / unclassified | 8 mg/kg | Intravenous |
| Subject | HS-20093 | Other / unclassified | 10 mg/kg | Intravenous |